Seth Klarman · Q4 2016
Baupost Group
Portfolio at the end of Q4 2016, from the 13F filed February 14, 2017. See the filing on EDGAR ↗
| Company | Weight | Held since | Change |
|---|---|---|---|
| Cheniere Energy LNG · history | 11.7% | Q1 2014 | Reduce 22% |
| Viasat VSAT · history | 11.4% | Q2 2013 or earlier | Add 14% |
| Synchrony SYF · history | 9.8% | Q3 2016 | Add 18% |
| Allergan AGN · history | 9.4% | Q1 2016 | Add 71% |
| Twenty-First Century Fox FOXA · history | 7.0% | Q3 2015 | Add 50% |
| PBF Energy PBF · history | 5.7% | Q3 2013 | No change |
| Dell Technologies DELL · history | 4.8% | Q3 2016 | No change |
| Antero Resources AR · history | 4.5% | Q3 2014 | No change |
| Theravance Biopharma TBPH · history | 3.9% | Q2 2014 | Add 26% |
| NorthStar Asset Management NSAM · history | 3.6% | Q3 2016 | Add 89% |
| NorthStar Realty Finance NRF · history | 2.9% | Q3 2016 | Add 165% |
| Twenty-First Century Fox FOX · history | 2.6% | Q3 2015 | No change |
| Veritiv VRTV · history | 2.1% | Q3 2014 | No change |
| Innoviva INVA · history | 2.1% | Q2 2013 or earlier | No change |
| Keryx Biopharmaceuticals KERX · history | 2.0% | Q1 2014 | No change |
| Colony Financial CLNY · history | 1.8% | Q3 2016 | Add 57% |
| McKesson MCK · history | 1.8% | Q4 2016 | Buy |
| Forward Pharma FWP · history | 1.0% | Q4 2014 | No change |
| Atara Biotherapeutics ATRA · history | 1.0% | Q4 2014 | No change |
| Cardinal Health CAH · history | 1.0% | Q4 2016 | Buy |
| Atlanta Braves Holdings BATRK · history | 0.8% | Q2 2016 | No change |
| American International Group AIG.WS · warrants · history | 0.8% | Q2 2013 or earlier | No change |
| Syngenta SYT · history | 0.8% | Q4 2016 | Buy |
| Liberty Ventures LVNTA · history | 0.7% | Q4 2016 | Buy |
| Credit Acceptance CACC · history | 0.7% | Q2 2016 | Add 144% |
| ChipMOS IMOS · history | 0.6% | Q2 2013 or earlier | Reduce 6% |
| GTY Technology GTYH.U · units · history | 0.6% | Q4 2016 | Buy |
| Permian Resources CDEV · history | 0.6% | Q4 2016 | Buy |
| Novagold Resources NG · history | 0.6% | Q2 2013 or earlier | No change |
| Cencora COR · history | 0.5% | Q4 2016 | Buy |
| Innoviva INVA.CV · convertible notes · history | 0.5% | Q3 2014 | Reduce 4% |
| Conyers Park Acquisition CPAA · history | 0.5% | Q3 2016 | No change |
| Theravance Biopharma TBPH.CV · convertible notes · history | 0.4% | Q4 2016 | Buy |
| Paratek Pharmaceuticals PRTK · history | 0.4% | Q4 2014 | No change |
| Saban Capital Acquisition SCAC · history | 0.3% | Q4 2016 | Buy |
| Cascadian Therapeutics CASC · history | 0.2% | Q2 2016 | Reduce 83% |
| Atlanta Braves Holdings BATRA · history | 0.2% | Q2 2016 | No change |
| Liberty Expedia LEXEA · history | 0.2% | Q4 2016 | Buy |
| Sunrun RUN · history | 0.2% | Q3 2015 | No change |
| Citigroup C.WS · warrants · history | 0.1% | Q2 2013 or earlier | Reduce 39% |
| Trilogy Metals TMQ · history | 0.1% | Q2 2013 or earlier | No change |
| Orexigen Therapeutics OREX · history | 0.1% | Q3 2015 | No change |
| Conyers Park Acquisition CPAA.WS · warrants · history | 0.0% | Q3 2016 | No change |
| Saban Capital Acquisition SCAC.WS · warrants · history | 0.0% | Q4 2016 | Buy |
| 44 positions | 100.0% |
Weight is the position's share of the total value in this 13F, not of the whole fund. Price is the value divided by the number of shares, so it's the price at the end of the quarter, as the firm reported it. Change compares share counts with Q3 2016, adjusted for stock splits.
Sector weighting
| Health care | 24.3% | |
|---|---|---|
| Energy | 22.5% | |
| Media & telecom | 22.0% | |
| Financials & real estate | 20.6% | |
| Technology | 6.0% | |
| Industrials | 2.3% | |
| Materials | 1.4% | |
| Consumer discretionary | 0.9% |
What changed from Q3 2016
- Buy McKesson MCK 1.8% of the 13F
- Buy Cardinal Health CAH 1.0% of the 13F
- Buy Syngenta SYT 0.8% of the 13F
- Buy Liberty Ventures LVNTA 0.7% of the 13F
- Buy GTY Technology GTYH.U 0.6% of the 13F
- Buy Permian Resources CDEV 0.6% of the 13F
- Buy Cencora COR 0.5% of the 13F
- Buy Theravance Biopharma TBPH.CV 0.4% of the 13F
- Buy Saban Capital Acquisition SCAC 0.3% of the 13F
- Buy Liberty Expedia LEXEA 0.2% of the 13F
- Buy Saban Capital Acquisition SCAC.WS 0.0% of the 13F
- Add 14% Viasat VSAT 12.2% → 11.4%
- Add 18% Synchrony SYF 7.0% → 9.8%
- Add 71% Allergan AGN 6.6% → 9.4%
- Add 50% Twenty-First Century Fox FOXA 4.4% → 7.0%
- Add 26% Theravance Biopharma TBPH 3.8% → 3.9%
- Add 89% NorthStar Asset Management NSAM 1.8% → 3.6%
- Add 165% NorthStar Realty Finance NRF 1.0% → 2.9%
- Add 57% Colony Financial CLNY 1.2% → 1.8%
- Add 144% Credit Acceptance CACC 0.3% → 0.7%
- Reduce 22% Cheniere Energy LNG 17.3% → 11.7%
- Reduce 6% ChipMOS IMOS 1.1% → 0.6%
- Reduce 4% Innoviva INVA.CV 0.6% → 0.5%
- Reduce 83% Cascadian Therapeutics CASC 0.6% → 0.2%
- Reduce 39% Citigroup C.WS 0.1% → 0.1%
- Sell PayPal PYPL was 2.9%
- Sell Olin OLN was 1.8%
- Sell VMware VMW was 1.7%
- Sell Qurate Retail QVCA was 1.4%
- Sell KLX KLXI was 1.0%
- Sell Silver Run Acquisition SRAQ was 0.8%
- Sell The ODP Corporation ODP was 0.7%
- Sell Saban Capital Acquisition SCAC.U was 0.3%
- Sell Kindred Biosciences KIN was 0.2%
- Sell Tobira Therapeutics TBRA was 0.1%
- Sell Silver Run Acquisition SRAQ.WS was 0.1%